^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
bioMérieux

i
Other names: bioMérieux | bioMérieux SA | bioMérieux - Sint-Martens-Latem
Related tests:
Evidence
News
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600E-Colorectal Cancer-cetuximab + encorafenib]
Source:
Published date:
09/28/2021
Excerpt:
ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of...BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)...in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600E-Melanoma-trametinib]
Source:
Excerpt:
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600E-Melanoma-dabrafenib]
Source:
Excerpt:
TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600E-Melanoma-binimetinib + encorafenib]
Source:
Excerpt:
BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600K-Melanoma-binimetinib + encorafenib]
Source:
Excerpt:
MEKTOVI is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600E-Melanoma-trametinib + dabrafenib]
Source:
Excerpt:
TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600K-Melanoma-trametinib + dabrafenib]
Source:
Excerpt:
TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Evidence Level:
Sensitive: A1 - Approval
[BRAF V600K-Melanoma-trametinib]
Source:
Excerpt:
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
Evidence Level:
Sensitive: A2 - Guideline
[BRAF V600E-Cutaneous Melanoma-binimetinib + encorafenib]
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...BRAF/MEK Combinations…Encorafenib/binimetinib…Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDAapproved test
Evidence Level:
Sensitive: A2 - Guideline
[BRAF V600K-Cutaneous Melanoma-binimetinib + encorafenib]
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...BRAF/MEK Combinations…Encorafenib/binimetinib…Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDAapproved test
Evidence Level:
Sensitive: A2 - Guideline
[BRAF V600E-Cutaneous Melanoma-dabrafenib]
Source:
Published date:
02/19/2021
Excerpt:
...NCCN Panel recommends BRAF inhibitor monotherapy only in those rare cases where combination therapy is contraindicated. In such cases, BRAF inhibitor monotherapy remains a treatment option especially if the patient is not an appropriate candidate for immune checkpoint inhibitor therapy. Dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib combination therapy regimens are FDA approved for the treatment of patients with unresectable or distant metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Evidence Level:
Sensitive: B - Late Trials
[BRAF V600E-Melanoma-trametinib + dabrafenib]
Title:
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Excerpt:
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
DOI:
10.1056/NEJMoa1412690
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
[BRAF V600E-Thyroid Gland Anaplastic Carcinoma-trametinib + dabrafenib]
Source:
Title:
Dabrafenib plus trametinib in patients with BRAF V600E–mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Published date:
01/10/2022
Excerpt:
We report an updated analysis describing the efficacy and safety of dabrafenib plus trametinib in the full ROAR ATC cohort of 36 patients....The investigator-assessed ORR was 56% (95% confidence interval, 38.1%-72.1%), including 3 complete responses; the 12-month DOR rate was 50%. Median PFS and OS were 6.7 and 14.5 months, respectively. Respective 12-month PFS and OS rates were 43.2% and 51.7%, and the 24-month OS rate was 31.5%....These updated results confirm the substantial clinical benefit and manageable toxicity of dabrafenib plus trametinib in BRAF V600E–mutant ATC.
DOI:
https://doi.org/10.1016/j.annonc.2021.12.014
Trial ID: